situs slot gacor slot gacor hari ini

Open Access Editorial

Individualized Hormone Replacement Therapy Versus Ovarian Transplantation

BM Petrikovsky1*, EV Zharov2 and M Cohen3

1Chairman of Obstetrics and Gynecology, Nassau University Medical Center, USA

2Russian Federation Academy of Science, Russia

3Private practice, Hartford, CT, USA

Corresponding Author

Received Date: February 09, 2019;  Published Date: February 12, 2019


Numerous studies conclude that risks and benefits of hormonal replacement therapy (HRT) are dose-dependent [1]. The pharmaceutical industry attempted to partially resolve the issue of individualization of HRT by manufacturing at least six different types of Minivelle patches (0.024mg, 0.0375mg, 0.05mg, 0.075mg, and 0.1mg). The choices offered by the pharmaceuticals are useful but fail to caliber dose based on the needs of the individual patient.

Signup for Newsletter
Scroll to Top